Why orphan drug coverage reimbursement decision-making needs patient and public involvement

Highlights • Patients and publics can play a role in orphan drugs coverage decision-making. • This could be in priority setting, criteria development, and technology assessment. • Empirical experimentation of involvement in these areas is needed. • Robust evaluations of those experiments will direct...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Health policy (Amsterdam) 2015-05, Vol.119 (5), p.588-596
Hauptverfasser:	Douglas, Conor M.W, Wilcox, Elizabeth, Burgess, Michael, Lynd, Larry D
Format:	Artikel
Sprache:	eng
Schlagworte:	Canada Cost Cost-Benefit Analysis Coverage Decision Making Diseases Drugs Economics, Pharmaceutical Government policy Health administration Health care Health Care Rationing Health economics Health policy Humans Insurance Coverage Insurance, Health, Reimbursement - economics Internal Medicine Medical service Orphan Drug Production - economics Orphan drugs Orphans Patient Participation Patients Policy Policy Making Public and patient involvement Rare diseases Rare Diseases - drug therapy Rationing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Patients and publics can play a role in orphan drugs coverage decision-making. • This could be in priority setting, criteria development, and technology assessment. • Empirical experimentation of involvement in these areas is needed. • Robust evaluations of those experiments will direct further future action.
ISSN:	0168-8510 1872-6054
DOI:	10.1016/j.healthpol.2015.01.009